Furosemide

10MG/ML, 10MG/ML injectableEstados UnidosComercializadoAutorizado el 10 ene 1979

Contenido en inglés

Indicaciones

Furosemide injection is a loop diuretic indicated for: The treatment of edema associated with heart failure, cirrhosis of the liver, and renal disease ( 1.1 ) Acute pulmonary edema as adjunctive therapy ( 1.2 )

1.1Edema

Furosemide injection is indicated in adults and pediatric patients for the treatment of edema associated with heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome.

1.2Acute Pulmonary Edema

Furosemide injection is indicated as adjunctive therapy in acute pulmonary edema.

Contraindicaciones

Furosemide injection is contraindicated in patients with anuria. Furosemide injection is contraindicated in patients with a history of hypersensitivity to furosemide. Anuria ( 4 ) Hypersensitivity to furosemide ( 4 )

Advertencias y precauciones

Fluid, Electrolyte, and Metabolic Abnormalities : Monitor serum electrolytes, CO2, BUN, creatinine, glucose, and uric acid ( 5.1 ) Worsening Renal Function : Monitor for dehydration and azotemia. ( 5.2 ) Ototoxicity: Avoid rapid injection and higher than recommended doses. ( 5.3 , 7.1 ) Acute Urinary Retention : Monitor patients with symptoms of urinary retention. ( 5.4 )

5.1Fluid, Electrolyte, and Metabolic Abnormalities

Furosemide may cause fluid, electrolyte, and metabolic abnormalities such as hypovolemia, hypokalemia, azotemia, hyponatremia, hypochloremic alkalosis, hypomagnesemia, hypocalcemia, hyperglycemia, or hyperuricemia, particularly in patients receiving higher doses, patients with inadequate oral electrolyte intake, and in elderly patients. Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients.

Indicaciones

1.1Edema

1.2Acute Pulmonary Edema

Furosemide injection is indicated as adjunctive therapy in acute pulmonary edema.

Advertencias y precauciones

5.1Fluid, Electrolyte, and Metabolic Abnormalities

Interacciones

Aminoglycoside antibiotics : Increased potential ototoxicity of the antibiotics. Avoid combination ( 7.1 ) Ethacrynic acid : Risk of ototoxicity. Avoid combination ( 7.1 ) Salicylates : Risk of salicylate toxicity ( 7.1 ) Cisplatin and nephrotoxic drugs : Risk of ototoxicity and nephrotoxicity ( 7.1 ) Lithium : Risk of lithium toxicity ( 7.1 ) Renin-angiotensin inhibitors : Increased risk of hypotension and renal failure.( 7.1 ) Adrenergic blocking drugs : Risk of potentiation ( 7.1 ) Drugs undergoing renal tubular secretion : Risk of toxicity potentiation ( 7.1 )

7.1 Effects of Furosemide on Other Drugs Drug/Substance Class or Name Drug Interaction Effect Recommendations Aminoglycoside antibiotics Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function [see Warnings and Precautions ( 5.3 )]. Avoid combination except in life-threatening situations. Ethacrynic acid Possibility of ototoxicity [see Warnings and Precautions ( 5.3 )].

Avoid concomitant use with ethacrynic acid. Salicylates May experience salicylate toxicity at lower doses because of competitive renal excretory sites. Monitor for symptoms of salicylate toxicity. Cisplatin There is a risk of ototoxic effects if cisplatin and furosemide are given concomitantly [see Warnings and Precautions ( 5.3 )]. Cisplatin and nephrotoxic drugs Nephrotoxicity Administer furosemide at lower doses and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment.

Monitor renal function. Paralytic agents Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine. Monitor for skeletal muscle effect. Lithium Furosemide reduces lithium’s renal clearance and add a high-risk of lithium toxicity. Avoid concomitant use with lithium. Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers May lead to severe hypotension and deterioration in renal function, including renal failure.

Monitor for changes in blood pressure and renal function and interrupt or reduce the dosage of furosemide, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers if needed. Antihypertensive drugs Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs. Monitor for changes in blood pressure and adjust the dose of other antihypertensive drugs if needed. Adrenergic blocking drugs or peripheral adrenergic blocking drugs Potentiation occurs.

Monitor for changes in blood pressure and adjust the dose of adrenergic blocking drugs if needed. Norepinephrine Furosemide may decrease arterial responsiveness (vasoconstricting effect) to norepinephrine. Monitor blood pressure (or mean arterial pressure). Chloral hydrate In isolated cases, intravenous administration of furosemide within 24 hours of taking chloral hydrate may lead to flushing, sweating attacks, restlessness, nausea, increase in blood pressure, and tachycardia.

Concomitant use with chloral hydrate is not recommended. Methotrexate and other drugs undergoing renal tubular secretion Furosemide may decrease renal elimination of other drugs that undergo tubular secretion. High-dose treatment of furosemide may result in elevated serum levels of these drugs and may potentiate their toxicity. Monitor serum levels of drugs undergoing renal tubular secretion and adjust the dose if needed.

Cephalosporin Furosemide can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment. Monitor for changes in renal function. Cyclosporine Increased risk of gouty arthritis secondary to furosemide-induced hyperuricemia and cyclosporine impairment of renal urate excretion. Monitor serum urate levels. Thyroid hormones High-doses (> 80 mg) of furosemide may inhibit the binding of thyroid hormones to carrier proteins and result in transient increase in free thyroid hormones, followed by an overall decrease in total thyroid hormone levels.

Monitor the total thyroid hormone levels.

7.2 Effects of Other Drugs on Furosemide Drug/Substance Class or Name Drug Interaction Effect Recommendations Phenytoin Interferes directly with renal action of furosemide. Monitor diuretic effects of furosemide and adjust the dose of furosemide if needed. Methotrexate and other drugs undergoing renal tubular secretion May reduce the effect of furosemide. High-dose treatment of methotrexate and these other drugs may result in elevated serum levels of furosemide and may potentiate the toxicity of furosemide.

Monitor for enhanced toxicity of furosemide. Indomethacin Coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis. Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation. Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.

Embarazo y lactancia

8.1Pregnancy Risk Summary

Available data from published observational studies, case reports, and postmarketing reports, from decades of use, have not demonstrated a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes with furosemide use during pregnancy. Untreated congestive heart failure and cirrhosis of the liver can lead to adverse outcomes for the mother and the fetus (see Clinical Considerations) .

In animal reproduction studies, furosemide has been shown to cause unexplained maternal deaths and abortions in rabbits when administered orally during organogenesis at 4 times a human i.v. dose of 80 mg based on body surface area (BSA) and oral bioavailability corrections, presumably secondary to volume depletion (see Data) . The estimated background risk for major birth defects and miscarriage for the indicated populations is unknown.

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in the clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Pregnant women with congestive heart failure are at increased risk for pre-term birth.

Stroke volume and heart rate increase during pregnancy, increasing cardiac output, especially during the first trimester. Clinical classification of heart disease may worsen with pregnancy and lead to maternal death and/or stillbirth. Closely monitor pregnant patients for destabilization of their heart failure. Pregnant women with symptomatic cirrhosis generally have poor outcomes including hepatic failure, variceal hemorrhage, pre-term delivery, fetal growth restriction and maternal death.

Outcomes are worse with coexisting esophageal varices. Pregnant women with cirrhosis of the liver should be carefully monitored and managed accordingly. Data Animal Data The effects of furosemide on embryonic and fetal development and on pregnant dams were studied in mice, rats and rabbits. Furosemide caused unexplained maternal deaths and abortions in the rabbit at the lowest dose of 25 mg/kg (approximately 4 times a human i.v. dose of 80 mg based on BSA and oral bioavailability corrections).

In another study, a dose of 50 mg/kg (approximately 7 times a human i.v. dose of 80 mg based on BSA and oral bioavailability corrections) also caused maternal deaths and abortions when administered to rabbits between Days 12 and 17 of gestation. In a third study, none of the pregnant rabbits survived an oral dose of 100 mg/kg. Data from the above studies indicate fetal lethality that can precede maternal deaths. The results of the mouse study and one of the three rabbit studies also showed an increased incidence and severity of hydronephrosis (distention of the renal pelvis and, in some cases, of the ureters) in fetuses of treated dams as compared with the incidence of fetuses from the control group.

Reacciones adversas

The following adverse reactions are described elsewhere in the labeling: Fluid, Electrolyte, and Metabolic Abnormalities [see Warnings and Precautions ( 5.1 )] Ototoxicity [see Warnings and Precautions ( 5.3 )] The following adverse reactions associated with the use of furosemide were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Adverse reactions are categorized below by organ system and listed by decreasing severity. Gastrointestinal System Reactions: pancreatitis, jaundice (intrahepatic cholestatic jaundice), increased liver enzymes, anorexia, oral and gastric irritation, cramping, diarrhea, constipation, nausea, vomiting. Systemic Hypersensitivity Reactions: severe anaphylactic or anaphylactoid reactions (e.g., with shock), systemic vasculitis, interstitial nephritis, necrotizing angiitis.

Central Nervous System Reactions: tinnitus and hearing loss, paresthesias, vertigo, dizziness, headache, blurred vision, xanthopsia. Hematologic Reactions: aplastic anemia, thrombocytopenia, agranulocytosis, hemolytic anemia, leukopenia, anemia, eosinophilia. Dermatologic-Hypersensitivity Reactions: toxic epidermal necrolysis, Stevens-Johnson Syndrome, erythema multiforme, drug rash with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis, exfoliative dermatitis, bullous pemphigoid, purpura, photosensitivity, rash.

Cardiovascular Reactions: orthostatic hypotension, increase in cholesterol and triglyceride serum levels. Other Reactions: glycosuria, muscle spasm, weakness, restlessness, urinary bladder spasm, thrombophlebitis, transient injection site pain following intramuscular injection, fever. Most common adverse reactions are related to fluid and electrolyte imbalance ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Presentación	Código	Estado
FUROSEMIDE 10MG/ML	ANDA202747-001	Prescription
FUROSEMIDE 10MG/ML	ANDA208435-001	Prescription
FUROSEMIDE 10MG/ML	ANDA214766-001	Prescription
FUROSEMIDE 10MG/ML	ANDA215856-001	Prescription
FUROSEMIDE 10MG/ML	ANDA070014-001	Discontinued
FUROSEMIDE 10MG/ML	ANDA070604-001	Discontinued
FUROSEMIDE 10MG/ML	NDA018420-001	Discontinued
FUROSEMIDE 10MG/ML	NDA018670-001	Discontinued
FUROSEMIDE 10MG/ML	ANDA203428-001	Prescription
FUROSEMIDE 10MG/ML	ANDA077941-001	Prescription
FUROSEMIDE 10MG/ML	NDA018507-001	Discontinued
FUROSEMIDE 10MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	NDA018579-001	Discontinued
FUROSEMIDE 10MG/ML	NDA018902-001	Prescription
FUROSEMIDE 10MG/ML	ANDA212803-001	Prescription
FUROSEMIDE 10MG/ML	ANDA070023-001	Discontinued
FUROSEMIDE 10MG/ML	ANDA213902-001	Prescription
FUROSEMIDE 10MG/ML	ANDA218188-001	Prescription
FUROSEMIDE 10MG/ML	ANDA074017-001	Discontinued
FUROSEMIDE 10MG/ML	NDA019036-001	Discontinued
FUROSEMIDE 10MG/ML	ANDA070017-001	Prescription
FUROSEMIDE 10MG/ML	ANDA070095-001	Discontinued
FUROSEMIDE 10MG/ML	NDA018667-001	Prescription
FUROSEMIDE 10MG/ML	ANDA216860-001	Prescription
FUROSEMIDE 10MG/ML	ANDA075241-001	Prescription
FUROSEMIDE 10MG/ML	ANDA207552-001	Prescription
FUROSEMIDE 10MG/ML	ANDA212174-001	Prescription
FUROSEMIDE 10MG/ML	ANDA070078-001	Discontinued
FUROSEMIDE 10MG/ML	ANDA070096-001	Discontinued
FUROSEMIDE 10MG/ML	ANDA070578-001	Discontinued
FUROSEMIDE 10MG/ML	ANDA070019-001	Discontinued

Furosemide

Indicaciones

1.1Edema

1.2Acute Pulmonary Edema

Contraindicaciones

Advertencias y precauciones

5.1Fluid, Electrolyte, and Metabolic Abnormalities

¿Dos medicamentos en una misma pregunta?

Furosemide

Indicaciones

1.1Edema

1.2Acute Pulmonary Edema

Contraindicaciones

Advertencias y precauciones

5.1Fluid, Electrolyte, and Metabolic Abnormalities

¿Dos medicamentos en una misma pregunta?

5.2Worsening Renal Function

5.3Ototoxicity Cases

5.4Acute Urinary Retention

Interacciones

Embarazo y lactancia

8.1Pregnancy Risk Summary

Reacciones adversas

En otros países

Presentaciones

Documentos

Fuentes y licencias

De un vistazo